Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 10/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7574173 | 0.90 | TSPO (0.69) | TSPOOPRK1ALB | |
| SCHEMBL2892630 | 0.83 | TSPO (0.57) | TSPOOPRK1SLC6A2HTR2ASLC6A4 | |
| SCHEMBL2890745 | 0.82 | TSPO (0.53) | TSPOOPRK1SLC6A2HTR2ASLC6A4 | |
| SCHEMBL7573859 | 0.81 | TSPO (0.69) | TSPOOPRK1ALB | |
| SCHEMBL14542291 | 0.77 | TSPO (0.77) | TSPOOPRK1ALB | |
| SCHEMBL2757574 | 0.77 | TSPO (0.70) | TSPOOPRK1ALB | |
| SCHEMBL7575533 | 0.77 | TSPO (0.82) | TSPOOPRK1ALB | |
| Ammonia Solution, Strong SCHEMBL7569838 | 0.76 | TSPO (0.75) | TSPOOPRK1ALB | |
| SCHEMBL2757581 | 0.76 | TSPO (0.69) | TSPOOPRK1ALB | |
| SCHEMBL7574707 | 0.76 | TSPO (0.80) | TSPOOPRK1ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8558028-B2 | Compound capable of inhibiting 17-beta hydroxysteriod dehydrogenase | UNIVERSITY OF BATH OF CLAVERTON DOWN (GB) | 2013-10-15 | — | — | US | disclosed |
| US-8558028-B2 | Compound capable of inhibiting 17-beta hydroxysteriod dehydrogenase | UNIVERSITY OF BATH OF CLAVERTON DOWN (GB) | 2013-10-15 | — | — | US | disclosed |
| US-8558028-B2 | Compound capable of inhibiting 17-beta hydroxysteriod dehydrogenase | UNIVERSITY OF BATH OF CLAVERTON DOWN (GB) | 2013-10-15 | — | — | US | disclosed |
| US-20100286204-A1 | COMPOUND CAPABLE OF INHIBITING 17-BETA HYDROXYSTERIOD DEHYDROGENASE | STERIX LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286204-A1 | COMPOUND CAPABLE OF INHIBITING 17-BETA HYDROXYSTERIOD DEHYDROGENASE | STERIX LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286204-A1 | COMPOUND CAPABLE OF INHIBITING 17-BETA HYDROXYSTERIOD DEHYDROGENASE | STERIX LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286204-A1 | COMPOUND CAPABLE OF INHIBITING 17-BETA HYDROXYSTERIOD DEHYDROGENASE | HSD17B13, HSD17B3, HSD3B2 | TSPO 928/4885OPRK1 401/4885SLC6A2 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.